Yahoo Web Search

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesSynovial Sarcoma: A Clinical Review - PMC

   www.ncbi.nlm.nih.gov › pmc › articles

   May 19, 2021 · Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation.

   • Figure 1

     AP (A) and lateral (B) radiographs of the right (R) knee and...

   • Local Recurrence of Disease After Unplanned Excisions of High-grade Soft Tissue Sarcomas

     Adjuvant therapy treatment decisions were made by the...

   • Magnetic Resonance and Computed Tomography Imaging Features and Differential Diagnostic Considerations

     Synovial sarcoma is considered the most common malignant...

2. www.ncbi.nlm.nih.gov › pmc › articlesSynovial sarcoma: characteristics, challenges, and evolving ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Aug 23, 2023 · Synovial sarcoma (SS) is a rare and malignant tumor of the connective tissues that presents challenges in diagnosis and treatment. 1,2 This article describes the epidemiology, clinical and genomic characteristics of SS, and the patient pathway from diagnosis to treatment.

   • DOI: 10.1016/j.esmoop.2023.101618
   • Published: 2023/10

   • Publication: ESMO Open. 2023 Oct; 8(5): 101618.

3. www.researchgate.net › publication › 351732367(PDF) Synovial Sarcoma: A Clinical Review - ResearchGate

   www.researchgate.net › publication › 351732367

   May 19, 2021 · Synovial sarcoma (SS) is an aggressive sarcoma subtype that accounts for 10% of all soft-tissue sarcomas, predominantly occurring in younger adults compared to other sarcomas (42).

4. www.ncbi.nlm.nih.gov › pmc › articlesSystemic Treatment for Adults with Synovial Sarcoma

   www.ncbi.nlm.nih.gov › pmc › articles

   Mar 7, 2018 · Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive.

   • Author: Ingrid M. E. Desar, Emmy D. G. Fleuren, Winette T. A. van der Graaf

   • Publish Year: 2018

5. www.mdpi.com › 1718/7729/28-3 › 177Synovial Sarcoma: A Clinical Review - MDPI

   www.mdpi.com › 1718/7729/28-3 › 177

   • Cached

   May 19, 2021 · Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation.

   • Author: Aaron M. Gazendam, Snezana Popovic, Sohaib Munir, Naveen Parasu, David Wilson, Michelle Ghert

   • Publish Year: 2021

6. link.springer.com › article › 10Synovial Sarcoma: Advances in Diagnosis and Treatment ...

   link.springer.com › article › 10

   • Cached

   Apr 10, 2017 · In this review, we present recent discoveries in the pathogenesis, diagnosis, and treatment of synovial sarcoma. We discuss potential therapeutic strategies to improve clinical outcomes in this disease.

7. People also ask

   How common is synovial sarcoma (SS)?

   • Synovial sarcoma (SS) accounts for 5–10% of all STS [1, 2]. SS is an intriguing disease as, unlike the majority of STS, it can occur at any age and everywhere in the body. The peak incidence is in the 30s and it often presents in the extremities [3 •].

   Systemic Treatment for Adults with Synovial Sarcoma

   www.ncbi.nlm.nih.gov/pmc/articles/PMC5842271/

   See all results for this question

   Is synovial sarcoma a subset of Sts?

   • Conclusions Synovial sarcomas (SS) represent a unique subset of STS and account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis, anatomic location (peri-articular) and clinical presentation (slow-growing, painful lesions).

   Synovial Sarcoma: A Clinical Review - PMC - National Center

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8161765/

   See all results for this question

   What is synovial sarcoma?

   • Synovial sarcoma is a relatively rare malignancy representing a soft tissue sarcoma (STS) of uncertain differentiation. It accounts for 5–10% of all STS [ 1, 2, 3 ].

   Synovial Sarcoma: A Clinical Review - PMC - National Center

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8161765/

   See all results for this question

   How is synovial sarcoma treated?

   • Synovial sarcomas have unique genomic characteristics and are driven by a pathognomonic t (X;18) chromosomal translocation and subsequent formation of the SS18:SSX fusion oncogenes. Surgical excision remains the mainstay of treatment with radiation therapy utilized in high-risk tumors.

   Synovial Sarcoma: A Clinical Review - PMC - National Center

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8161765/

   See all results for this question

   How long does a synovial sarcoma last?

   • Synovial sarcomas often do not present with the typical STS presentation of a large and quickly growing painless mass [ 9 ]. Instead, the majority of synovial sarcomas are slow growing and the mean duration of symptoms before diagnosis is approximately 2 years [ 12 ].

   Synovial Sarcoma: A Clinical Review - PMC - National Center

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8161765/

   See all results for this question

   Can synovial sarcoma be excluded from differential diagnosis?

   • Synovial sarcoma cannot be entirely excluded from the differential diagnosis if tumors have the morphological and clinical features of synovial sarcoma but do not bear an SS18-SSX fusion gene. In rare instances (estimated to be <5% of all cases), synovial sarcomas do not carry the characteristic SS18-SSX transcripts.

   Synovial Sarcoma: Advances in Diagnosis and Treatment

   link.springer.com/article/10.1245/s10434-017-5855-x

   See all results for this question

8. ascopubs.org › doi › pdfSynovial Sarcoma: Current Concepts and Future Perspectives

   ascopubs.org › doi › pdf

   Dec 8, 2017 · Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. With approximately 800 to 1,000 cases a year in the United States, it most commonly affects young adults between the ages of 15 and 30 years.